Last 27 quarters of trend data · Healthcare · Oncology Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -1.11 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.61 | 4.58 | 0.82 | 0.21 | 0.72 | 0.52 | 0.40 | 0.31 | 0.32 | 0.33 | 0.30 | 9.00 | 5.34 | 5.75 | 8.78 | 9.76 | 8.86 | 8.35 | 11.07 | 10.46 | 24.22 |
| — | +783.7% | +105.9% | -31.2% | +125.4% | +57.7% | +32.8% | -96.6% | -94.0% | -94.3% | -96.6% | -7.9% | -39.7% | -31.2% | -20.7% | -6.7% | -63.4% | -79.9% | -69.8% | -67.4% | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | 94.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -74.0% | -12.0% | -8.8% | -162.3% | -22.7% | -18.2% | -16.6% | -19.5% | -18.5% | -14.8% | -13.7% | -13.0% | -10.9% | -9.5% | -10.8% | -10.3% | -11.3% | -11.2% | -8.1% | -8.8% | -6.2% |
| — | +34.1% | +47.2% | -732.0% | -22.8% | -22.6% | -21.7% | -50.6% | -69.2% | -56.1% | -26.9% | -26.2% | +3.0% | +15.2% | -33.7% | -16.6% | -81.3% | -83.8% | -38.0% | -3.3% | +80.8% | |
| ROA | -61.8% | -11.1% | -8.1% | -149.1% | -18.7% | -15.4% | -14.1% | -16.4% | -15.8% | -12.8% | -11.9% | -11.3% | -9.5% | -8.3% | -9.5% | -9.0% | -9.9% | -10.1% | -7.3% | -8.2% | -6.0% |
| — | +28.0% | +42.4% | -808.6% | -18.6% | -20.0% | -18.0% | -44.9% | -65.8% | -54.2% | -25.7% | -26.0% | +4.0% | +17.3% | -29.9% | -9.9% | -66.2% | -70.8% | -28.1% | -0.5% | +84.4% | |
| ROIC | -76.6% | -11.0% | -14.8% | -498.5% | -28.7% | -22.9% | -18.3% | -19.0% | -17.3% | -15.3% | — | -11.8% | -9.8% | -8.1% | -8.9% | -8.8% | -8.8% | -8.9% | -6.2% | -6.8% | -4.9% |
| — | +51.8% | +19.3% | -2529.8% | -65.6% | -49.2% | — | -61.1% | -76.8% | -88.7% | — | -34.1% | -11.7% | +8.3% | -45.0% | -30.0% | -79.3% | -69.0% | +36.7% | +98.6% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.08 | 0.00 | 0.00 | 0.01 | 0.08 | 0.09 | 0.09 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.10 | 0.09 | 0.08 | 0.08 | 0.07 | 0.07 | 0.07 | 0.02 |
| — | -99.0% | -96.3% | -94.6% | -19.0% | -10.0% | -3.1% | +4.0% | +4.7% | +2.3% | +5.4% | +18.0% | +23.1% | +29.4% | +33.1% | +21.9% | +383.5% | +1173.3% | +1882.7% | +1593.2% | -62.7% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 5.06 | 16.12 | 19.69 | 14.39 | 5.06 | 5.81 | 7.64 | 6.82 | 7.70 | 8.84 | 10.90 | 12.07 | 11.92 | 11.86 | 15.13 | 13.00 | 11.98 | 13.95 | 23.46 | 18.27 | 30.38 |
| — | +177.3% | +157.9% | +110.9% | -34.3% | -34.2% | -30.0% | -43.4% | -35.4% | -25.5% | -28.0% | -7.2% | -0.5% | -15.0% | -35.5% | -28.8% | -60.6% | -53.6% | -44.4% | -73.8% | +631.0% | |
| Quick Ratio | 5.06 | 16.12 | 19.69 | 14.39 | 5.06 | 5.81 | 7.64 | 6.82 | 7.70 | 8.84 | 10.90 | 12.07 | 11.92 | 11.86 | 15.13 | 13.00 | 11.98 | 13.95 | 23.46 | 18.27 | 30.38 |
| — | +177.3% | +157.9% | +110.9% | -34.3% | -34.2% | -30.0% | -43.4% | -35.4% | -25.5% | -28.0% | -7.2% | -0.5% | -15.0% | -35.5% | -28.8% | -60.6% | -53.6% | -44.4% | -73.8% | +631.0% | |
| Interest Coverage | -657.91 | — | — | — | -1571.33 | -760.50 | -492.60 | -527.00 | -456.06 | -344.38 | -296.58 | -284.43 | -238.16 | -214.88 | -246.00 | -241.31 | — | -1340.60 | -60.25 | -50.05 | -29.61 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 27 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FTH stock.
Faeth Therapeutics, Inc.'s current P/E is -1.1x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Faeth Therapeutics, Inc.'s business trajectory between earnings reports.